PavlovićAPolovinaMRistićAet al.Long-term mortality is increased in patients with undetected prediabetes and type 2 diabetes hospitalized for worsening heart failure and reduced ejection fraction. Eur J Prev Cardiol. 2019; 26: 72–82
2.
AmbrosyAPFonarowGCButlerJet al.The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol2014; 63: 1123–1133.
3.
ChioncelOMebazaaAHarjolaVPet al.Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. Eur J Heart Fail2017; 19: 1242–1254.
4.
Dei CasAKhanSSButlerJet al.Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. JACC Heart Fail2015; 3: 136–145.
5.
ChioncelOLainscakMSeferovicPMet al.Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail2017; 19: 1574–1585.
6.
JørgensenMEAnderssonCVasanRSet al.Characteristics and prognosis of heart failure with improved compared with persistently reduced ejection fraction: a systematic review and meta-analyses. Eur J Prev Cardiol2018; 25: 366–376.
7.
TargherGDaurizMLarocheCet al.on behalf of the ESC-HFA HF Long-term Registry Investigators. In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure. Results from the ESC-HFA Heart Failure Long-Term Registry. Eur J Heart Fail2017; 19: 54–65.
8.
Crespo-LeiroMGAnkerSDMaggioniAPet al.European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail2016; 18: 613–625.
9.
MebazaaAGayatELassusJet al.GREAT Network. Association between elevated blood glucose and outcome in acute heart failure. J Am Coll Cardiol2013; 61: 820–829.
10.
KristensenSLJhundPSLeeMMet al.CHARM Investigators and Committees. Prevalence of prediabetes and undiagnosed diabetes in patients with HFpEF and HFrEF and associated clinical outcomes. Cardiovasc Drugs Ther2017; 31: 545–549.
11.
DaurizMTargherGTemporelliPLet al.GISSI-HF Investigators. Prognostic impact of diabetes and prediabetes on survival outcomes in patients with chronic heart failure: a post-hoc analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) Trial. J Am Heart Assoc2017; 6: e005156–e005156.
12.
KristensenSLPreissDJhundPSet al.PARADIGM-HF Investigators and Committees. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circ Heart Fail2016; 9: e002560–e002560.
13.
BanerjeeSPetersonLR. Myocardial metabolism and cardiac performance in obesity and insulin resistance. Curr Cardiol Rep2007; 9: 143–149.
14.
TenenbaumAFismanEZ. Impaired glucose metabolism in patients with heart failure: pathophysiology and possible treatment strategies. Am J Cardiovasc Drugs2004; 4: 269–280.
15.
KostisJBSandersM. The association of heart failure with insulin resistance and development of type 2 diabetes. Am J Hypertens2005; 18: 731–737.
16.
MansourAAWanooseHL. Acute phase hyperglycemia among patients hospitalized with acute coronary syndrome: prevalence and prognostic significance. Oman Med J2011; 26: 85–90.
17.
ChioncelOCollinsSPAmbrosyAPet al.Improving post-discharge outcomes in acute heart failure. Am J Therapeut2018; 25: e475–e486.
18.
PreiserJCDevosPRuiz-SantanaSet al.A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol Study. Intens Care Med2009; 35: 1738–1748.
19.
FinferSChittockDRSuSYet al.NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med2009; 360: 1283–1297.
20.
RydenLGrantPJAnkerSDet al.ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, prediabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J2013; 34: 3035–3087.
21.
UsmanMSSiddiqiTJMemonMMet al.Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: a systematic review and meta-analysis. Eur J Prev Cardiol2018; 25: 495–502.
22.
ClinicalTrials.gov. EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced). https://clinicaltrials.gov/ct2/show/NCT03057977 (accessed 5 October 2018).
23.
ClinicalTrials.gov. Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure (Dapa-HF). https://clinicaltrials.gov/ct2/show/NCT03036124 (accessed 5 October 2018).
